Integrating single-cell transcriptomics and network pharmacology identifies ADORA1 as a candidate receptor for gastrodin derivatives in lung adenocarcinoma.
These analyses nominate ADORA1 as a candidate receptor and Gastrodin_T9 as a lead among gastrodin derivatives in LUAD; both candidates warrant mechanistic validation in LUAD-specific models.